Kilroy Conor 4

What Happened Conor Kilroy, Chief Legal Officer and Secretary of Aura Biosciences (AURA), was granted equity awards on 2026-03-02: 62,339 restricted stock units (RSUs) and 112,661 derivative awards (options/option-like awards). Both grants were recorded at $0.00 (no cash purchase); total awards equal 175,000 underlying shares. These awards are compensation grants rather than open-market purchases or sales.

Key Details

• Transaction date and price: 2026-03-02, acquired at $0.00 per share.
• Award breakdown: 62,339 RSUs (F1) and 112,661 derivative/option-linked awards (F2).
• Vesting:
  • RSUs (F1): vest in four substantially equal annual installments beginning January 15, 2027, subject to continued service.
  • Derivative/option (F2): 25% vests on February 1, 2027, remainder vests pro rata over the following 36 months, subject to continued service.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Filing timeliness: Report filed 2026-03-03 for a 2026-03-02 transaction (appears timely).
• Role note: Reporting person is Chief Legal Officer and Secretary (per filing remarks).

Context These awards are typical executive compensation grants. RSUs convert to common stock only as they vest; the derivative award vests over time and is subject to service conditions. No shares were sold or purchased on the open market in this filing, and no immediate cashless exercise or sale was reported.